You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Ruthenium-bipyridine-trimethylphosphine caged glutamate that can be excited by visible wavelengths and releases glutamate after one- or two-photon excitation. Has high quantum efficiency and can be used at low concentrations, partly avoiding blockade of GABAergic transmission seen with other caged glutamate compounds. Displays high spatial resolution and generates excitatory responses in individual dendritic spines with physiological kinetics.
Sold under licence from Columbia University
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 970.54. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||5.15 mL||25.76 mL||51.52 mL|
|1 mM||1.03 mL||5.15 mL||10.3 mL|
|2 mM||0.52 mL||2.58 mL||5.15 mL|
|10 mM||0.1 mL||0.52 mL||1.03 mL|
References are publications that support the biological activity of the product.
Fino et al (2009) RuBi-Glutamate: two-photon and visible-light photoactivation of neurons and dendritic spines. Front.Neural Circuits 3 1 PMID: 19506708
Salierno et al (2010) A fast ruthenium polypyridine cage complex photoreleases glutamate with visible or IR light in one and two photon regimes. J.Inorg.Biochem. 104 418 PMID: 20060592
If you know of a relevant reference for RuBi-Glutamate, please let us know.
View Related Products by Target
Keywords: RuBi-Glutamate, RuBi-Glutamate supplier, Caged, Glutamate, mGluR, iGluR, Receptors, agonists, ionotropic, metabotropic, Miscellaneous, Compounds, 3574, Tocris Bioscience
4 Citations for RuBi-Glutamate
Citations are publications that use Tocris products. Selected citations for RuBi-Glutamate include:
Kazemipour et al (2019) Kilohertz frame-rate two-photon tomography. Nat Methods 16 778 PMID: 31363222
Tazerart et al (2019) Spike-timing-dependent plasticity rule for single, clustered and distributed dendritic spines BioRXiv
Paz et al (2018) Inhibition of striatal cholinergic interneuron activity by the Kv7 opener retigabine and the nonsteroidal anti-inflammatory drug diclofenac. Neuropharmacology 137 309 PMID: 29758221
Blaesse et al (2015) μ-Opioid Receptor-Mediated Inhibition of Intercalated Neurons and Effect on Synaptic Transmission to the Central Amygdala. Neuroscience 35 7317 PMID: 25972162
Do you know of a great paper that uses RuBi-Glutamate from Tocris? Please let us know.
Reviews for RuBi-Glutamate
There are currently no reviews for this product. Be the first to review RuBi-Glutamate and earn rewards!
Have you used RuBi-Glutamate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.